CLINICAL ENDPOINTS	LEQEMBI 10 mg/kg BIWEEKLY	PLACEBO
CDR-SB	N=859	N=875
MEAN BASELINE	3.17	3.22
ADJUSTED MEAN CHANGE FROM BASELINE AT 18 MONTHS DIFFERENCE FROM PLACEBO	1.213 -0.451 (P=0.00005)	1.663
ADAS-Cog14	N=854	N=872
MEAN BASELINE	24.45	24.37
ADJUSTED MEAN CHANGE FROM BASELINE AT 18 MONTHS DIFFERENCE FROM PLACEBO	4.140 -1.442 (P=0.00065)	5.581
ADCS MCI-ADL	N=783	N=796
MEAN BASELINE	41.2	40.9
ADJUSTED MEAN CHANGE FROM BASELINE AT 18 MONTHS DIFFERENCE FROM PLACEBO	-3.484 2.016 (P<0.00001)	-5.500

FIG. 1



ADJUSTED MEAN CHANGE FROM BASELINE (+/-SE)
0
0.5
1
1.5
PLACEBO
10 mg/kg EVERY TWO WEEKS
**
**
****
***
****
VISIT (MONTH): 0 3 6 9 12 15 18
N (PLACEBO): 875 849 828 813 779 767 757
N (10 mg/kg EVERY TWO WEEKS): 859 824 798 779 765 738 714
* P<0.05 ** P<0.01 *** P<0.001 **** P<0.0001

FIG. 2



ADJUSTED MEAN CHANGE FROM BASELINE (+/-SE)
0
1
2
3
4
5
6
PLACEBO
10 mg/kg EVERY TWO WEEKS
*
****
****
****
***
VISIT (MONTH): 0 3 6 9 12 15 18
N (PLACEBO): 872 844 823 807 770 762 738
N (10 mg/kg EVERY TWO WEEKS): 854 819 793 771 753 730 703
* P<0.05 ** P<0.01 *** P<0.001 **** P<0.0001

FIG. 3



ADJUSTED MEAN CHANGE FROM BASELINE (+/-SE)
0
-1
-2
-3
-4
-5
-6
PLACEBO
10 mg/kg EVERY TWO WEEKS
**
****
****
VISIT (MONTH): 0 6 12 18
N (PLACEBO): 796 783 739 707
N (10 mg/kg EVERY TWO WEEKS): 783 756 716 676
* P<0.05 ** P<0.01 *** P<0.001 **** P<0.0001

FIG. 4



ADJUSTED MEAN CHANGE FROM BASELINE (+/-SE)
10
0
-10
-20
-30
-40
-50
-60
PLACEBO
10 mg/kg EVERY TWO WEEKS
****
****
****
****
VISIT (MONTH): 0 3 6 12 18
N (PLACEBO): 344 303 286 259 205
N (10 mg/kg EVERY TWO WEEKS): 354 296 275 276 210
**** P<0.0001

FIG. 5



WORSENING
ADJUSTED MEAN CHANGE FROM BASELINE (±SE) IN EQ-5D-5L (HEALTH TODAY SUBJECT)
0
-0.5
-1
-1.5
-2
-2.5
-3
-3.5
-4
-4.5
-5
PLACEBO
LECANEMAB
49% LESS DECLINE
**
VISIT (MONTH): 0 6 12 18
N (PLACEBO): 848 835 783 754
(N) LECANEMAB: 833 811 762 715

FIG. 6



QOL-AD (SUBJECT)
56%
LESS DECLINE
**
PLACEBO
LECANEMAB
0
-0.5
-1
-1.5
WORSENING
ADJUSTED MEAN CHANGE
FROM BASELINE (±SE)
IN QOL-AD
(TOTAL SCORE SUBJECTS)
VISIT (MONTH): 0 6 12 18
N (PLACEBO): 849 834 786 753
(N) LECANEMAB: 832 811 763 715

FIG. 7



QOL-AD (SUBJECT BY PROXY)
23% LESS DECLINE
PLACEBO
LECANEMAB
****
*
WORSENING
ADJUSTED MEAN CHANGE FROM BASELINE (±SE) IN QOL-AD (TOTAL SCORE SUBJECTS BY PROXY)
0
-0.5
-1
-1.5
-2
-2.5
-3
VISIT (MONTH): 0 6 12 18
N (PLACEBO): 847 830 782 754
(N) LECANEMAB: 830 805 759 713
* P<0.05; ** P<0.01; *** P<0.001; **** P<0.0001

FIG. 8



ZARIT BURDEN INTERVIEW
STUDY PARTNER BURDEN (TOTAL SCORE)
38%
LESS DECLINE
PLACEBO
LECANEMAB
***
****
****
WORSENING
ADJUSTED MEAN CHANGE
FROM BASELINE (±SE)
IN ZARIT'S BURDEN INTERVIEW
OF STUDY PARTNER
0
1
2
3
4
5
6
7
VISIT (MONTH): 0 6 12 18
N (PLACEBO): 847 827 785 755
(N) LECANEMAB: 831 804 759 712
* P<0.05; ** P<0.01; *** P<0.001; **** P<0.0001

FIG. 9



TIME TO WORSENING OF GLOBAL CDR SCORE
RATE OF PROGRESS TO NEXT STAGE
0.0
0.1
0.2
0.3
PLACEBO
LECANEMAB
0
3
6
9
12
15
18
VISIT (MONTHS)
N (PLACEBO): 875 792 757 649 603 524 265 *
(N) LECANEMAB: 859 801 765 677 642 554 299 *

FIG. 10



EXTRAPOLATED DATA
OBSERVED DATA
1.64
0.68
2.32
7.5 M
1.16
0.48
5.3 M
PLACEBO
LECANEMAB
0
0.4
0.8
1.2
1.6
2
2.4
0
3
6
9
12
15
18
24
25.5
VISIT (MONTH)
WORSENING
ANALYSIS OF RATE OF CHANGE OVER TIME
(SLOPE ANALYSIS) IN CDR-SB

FIG. 11



ADJUSTED MEAN CHANGE FROM BASELINE
(±SE) IN PLASMA GFAP (pg/mL)
40
20
0
-20
-40
-60
PLACEBO
LECANEMAB
0
6
12
18
VISIT (MONTHS)
N (PLACEBO): 730 630 595 552
(N) LECANEMAB: 736 630 600 560

FIG. 12

CLARITY AD DOUBLE-BLIND CORE PERIOD

	ARIA		ARIA-E		MICROHEMORRHAGE		SUPERFICIAL SIDEROSIS		INTRACEREBRAL HEMORRHAGE	
	PLACEBO	LECANEMAB	PLACEBO	LECANEMAB	PLACEBO	LECANEMAB	PLACEBO	LECANEMAB	PLACEBO	LECANEMAB
NO ANTIPLATELET OR ANTICOAGULATION AT ANY TIME	52/586 (8.9%)	123/564 (21.8%)	9/586 (1.5%)	74/564 (13.1%)	42/586 (7.2%)	79/564 (14%)	13/586 (2.2%)	32/564 (5.7%)	0/586 (0%)	3/564 (0.5%)
EVENT POST ANY ANTIPLATELET (ASPIRIN OR NON-ASPIRIN)	23/237 (9.7%)	45/251 (17.9%)	2/237 (0.84%)	26/251 (10.4%)	18/237 (7.6%)	31/251 (12.4%)	5/237 (2.1%)	13/251 (5.2%)	1/237 (0.4%)	1/251 (0.4%)
EVENT POST ANY ANTICOAGULATION (ALONE OR WITH ANTIPLATELET)	8/74 (10.8%)	11/83 (13.3%)	2/74 (2.7%)	4/83 (4.8%)	7/74 (9.5%)	8/83 (9.6%)	2/74 (2.7%)	3/83 (3.6%)	0/74 (0%)	2/83 (2.4%)[1]

[1]INCLUDES ONE NON-TREATMENT EMERGENT CASE ON ANTICOAGULATION (EVENT > 30 DAYS AFTER DISCONTINUING STUDY MEDICATION)

FIG. 13

CLARITY AD DOUBLE-BLIND CORE PERIOD: CONSISTENT WITH OVERALL ANALYSIS

		ARIA		ARIA-E		MICROHEMORRHAGE		SUPERFICIAL SIDEROSIS		INTRACEREBRAL HEMORRHAGE	
		PLACEBO	LECANEMAB	PLACEBO	LECANEMAB	PLACEBO	LECANEMAB	PLACEBO	LECANEMAB	PLACEBO	LECANEMAB
NON-CARRIERS	NOT ON ANTIPLATELET OR ANTICOAGULATION AT ANY TIME	5/183 (2.7%)	27/182 (14.8%)	1/183 (0.5%)	13/182 (7.1%)	4/183 (2.2%)	13/182 (7.1%)	1/183 (0.5%)	10/182 (5.5%)	0/183 (0%)	1/182 (0.5%)
	EVENT POST ANY ANTIPLATELET (ASPIRIN OR NON-ASPIRIN)	6/79 (7.6%)	7/74 (9.5%)	0/79 (0%)	1/74 (1.4%)	4/79 (5.1%)	4/74 (5.4%)	1/79 (1.3%)	3/74 (4.1%)	1/79 (1.3%)	0/74 (0%)
	EVENT POST ANY ANTICOAGULATION (ALONE OR WITH ANTIPLATELET)	0/24 (0%)	4/22 (18.2%)	0/24 (0%)	1/22 (4.5%)	0/24 (0%)	3/22 (13.6%)	0/24 (0%)	0/22 (0%)	0/24 (0%)	0/22 (0%)
HETEROZYGOTES	NOT ON ANTIPLATELET OR ANTICOAGULATION AT ANY TIME	30/311 (9.6%)	54/283 (19.1%)	6/311 (1.9%)	32/283 (11.3%)	24/311 (7.7%)	33/283 (11.7%)	9/311 (2.9%)	10/283 (3.5%)	0/311 (0%)	2/283 (0.7%)
	EVENT POST ANY ANTIPLATELET (ASPIRIN OR NON-ASPIRIN)	9/124 (7.3%)	24/145 (16.6%)	1/124 (0.8%)	13/145 (9.0%)	6/124 (4.8%)	17/145 (11.7%)	3/124 (2.4%)	6/145 (4.1%)	0/124 (0%)	0/145 (0%)
	EVENT POST ANY ANTICOAGULATION (ALONE OR WITH ANTIPLATELET)	5/43 (11.6%)	8/51 (19.6%)	1/43 (2.3%)	4/51 (7.8%)	4/43 (9.3%)	5/51 (9.8%)	1/43 (2.3%)	2/51 (3.9%)	0/43 (0%)	1/51[1] (2.0%)

TO FIG. 14 (CONT.)

FIG. 14

FROM FIG. 14

HOMOZYGOTES

NOT ON ANTIPLATELET OR ANTICOAGULATION AT ANY TIME	17/92 (18.5%)	42/99 (42.4%)	2/92 (2.2%)	29/99 (29.3%)	14/92 (15.2%)	33/99 (33.3%)	3/92 (3.3%)	12/99 (12.1%)	0/92 (0%)	0/99 (0%)
EVENT POST ANY ANTIPLATELET (ASPIRIN OR NON-ASPIRIN)	8/34 (23.5%)	14/32 (43.8%)	1/34 (2.9%)	12/32 (37.5%)	8/34 (23.5%)	10/32 (31.3%)	1/34 (2.9%)	4/32 (12.5%)	0/34 (0%)	1/32 (3.1%)
EVENT POST ANY ANTICOAGULATION (ALONE OR WITH ANTIPLATELET)	3/7 (42.9%)	1/10 (10.0%)	1/7 14.3%)	2/10 (20.0%)	3/7 (42.9%)	2/10 (20.0%)	1/7 (14.3%)	2/10 (20.0%)	0/7 (0%)	1/10 (10.0%)

[1]INCLUDES ONE NON-TREATMENT EMERGENT CASE ON ANTICOAGULATION (EVENT > 30 DAYS AFTER DISCONTINUING STUDY MEDICATION)
AD, ALZHEIMER'S DIEASE; ARIA, AMYLOID REALTED IMAGINING ABNOMALITIES; ARIA-E, AMYLOID RELATED IMAGINING ABNORMALITIES - EDEMA.

FIG. 14 (CONT.)

CLARITY AD CORE AND OLE

301 CORE+OLE	ARIA	ARIA-E	MICROHEMORRHAGE	SUPERFICIAL SIDEROSIS	INTRACEREBRAL HEMORRHAGE
	LECANEMAB	LECANEMAB	LECANEMAB	LECANEMAB	LECANEMAB
NO ANTIPLATELET OR ANTICOAGULATION AT ANY TIME	229/1023 (22.4%)	134/1023 (13.1%)	157/1023 (15.3%)	61/1023 (6.0%)	4/1023 (0.4%)
EVENT POST ANY ANTIPLATELET (ASPIRIN OR NON-ASPIRIN)	93/433 (21.5%)	56/433 (12.9%)	65/433 (15.0%)	21/433 (4.8%)	1/433 (0.2%)
EVENT POST ANY ANTICOAGULATION (ALONE OR WITH ANTIPLATELET)	27/156 (17.3%)	17/156 (10.9%)	20/156 (12.8%)	9/156 (5.8%)	4/156 (2.6%)[1]

[1]INCLUDES ONE NON-TREATMENT EMERGENT CASE ON ANTICOAGULATION (EVENT > 30 DAYS AFTER DISCONTINUING STUDY MEDICATION)

FIG. 15

CLARITY AD CORE AND OLE: CONSISTENT WITH OVERALL ANALYSIS

	301 CORE+OLE	ARIA	ARIA-E	MICROHEMORRHAGE	SUPERFICIAL SIDEROSIS	INTRACEREBRAL HEMORRHAGE
		LECANEMAB	LECANEMAB	LECANEMAB	LECANEMAB	LECANEMAB
NON-CARRIERS	NOT ON ANTIPLATELET OR ANTICOAGULATION AT ANY TIME	41/320 (12.8%)	21320 (6.6%)	20/320 (6.3%)	16/320 (5.0%)	1/320 (0.3%)
NON-CARRIERS	EVENT POST ANY ANTIPLATELET (ASPIRIN OR NON-ASPIRIN)	20/129 (15.5%)	6/129 (4.7%)	13/129 (10.1%)	6/129 (4.7%)	0/129 (0%)
NON-CARRIERS	EVENT POST ANY ANTICOAGULATION (ALONE OR WITH ANTIPLATELET)	6/47 (12.8%)	3/47 (6.4%)	5/47 (10.6%)	0/47 (0%)	1/47 (2.1%)
HETEROZYGOTES	NOT ON ANTIPLATELET OR ANTICOAGULATION AT ANY TIME	109/530 (20.6%)	60/530 (11.3%)	76/530 (14.3%)	25/530 (4.7%)	2/530 (0.4%)
HETEROZYGOTES	EVENT POST ANY ANTIPLATELET (ASPIRIN OR NON-ASPIRIN)	45/245 (18.4%)	25/245 (10.2%)	32/245 (13.1%)	9/245 (3.7%)	0/245 (0%)
HETEROZYGOTES	EVENT POST ANY ANTICOAGULATION (ALONE OR WITH ANTIPLATELET)	14/92 (15.2%)	10/92 (10.9%)	10/92 (10.9%)	6/92 (6.5%)	2/92 (2.2%)

TO FIG. 16 (CONT.)

FIG. 16

FROM FIG. 16

HOMOZYGOTES

NOT ON ANTIPLATELET OR ANTICOAGULATION AT ANY TIME	79/173 (45.7%)	53/173 (30.6%)	61/173 (35.3%)	20/173 (11.6%)	1/173 (0.6%)
EVENT POST ANY ANTIPLATELET (ASPIRIN OR NON-ASPIRIN)	28/59 (47.5%)	25/59 (42.4%)	20/59 (33.9%)	6/59 (10.2%)	1/59 (1.7%)
EVENT POST ANY ANTICOAGULATION (ALONE OR WITH ANTIPLATELET)	7/17 (41.2%)	4/17 (23.5%)	5/17 (29.4%)	3/17 (17.6%)	1/17 (5.9%)

[1]INCLUDES ONE NON-TREATMENT EMERGENT CASE ON ANTICOAGULATION (EVENT > 30 DAYS AFTER DISCONTINUING STUDY MEDICATION)

FIG. 16
(CONT.)



MODEL-BASED PREDICTION OF ARIA-E RATES
%INCIDENCE OF ARIA-E
SERUM LECANEMAB CMAX,ss (µg/mL)
0
10
20
30
40
50
60
0
75
150
225
300
375
450
SC VIAL
AI
IV
APOE4 GENOTYPE
NON-CARRIER
HETEROZYGOUS
HOMOZYGOUS

FIG. 17




FIG. 18

ENDPOINTS	PLACEBO N = 875	LECANEMAB N = 859
CDR-SB, MEAN (SD) [SCALE RANGE: 0 (BEST) - 18 (WORST)]	**3.22** (1.343)	**3.17** (1.340)
AMYLOID PET CENTILOIDS, MEAN (SD)	**75.03** (41.82)	**77.92** (44.84)
ADAS-COG14, MEAN (SD) [SCALE RANGE: 0 (BEST) - 90 (WORST)]	**24.37** (7.561)	**24.45** (7.082)
ADCOMS, MEAN (SD) [SCALE RANGE: 0 (BEST) - 1.97 (WORST)]	**0.400** (0.15)	**0.398** (0.15)
ADCS MCI-ADL, MEAN (SD) [SCALE RANGE: 0 (WORST) - 53 (BEST)]	**40.9**(6.89)	**41.2** (6.61)

FIG. 19

ENDPOINT	MEASURE, CHANGE FROM BASELINE AT 18 MONTHS	LECANEMAB VS PLACEBO mITT FAS+
PRIMARY EFFICACY	**CDR-SB**	
	DIFFERENCE IN ADJUSTED MEAN (95% CI)	**-0.451** (-0.669, -0.233)
	P-VALUE VS PLACEBO	0.00005
KEY SECONDARY EFFICACY	**AMYLOID PET CENTILOIDS**	
	DIFFERENCE IN ADJUSTED MEAN (95% CI)	**-59.12** (-62.64, -55.60)
	P-VALUE VS PLACEBO	<0.00001
	ADAS-COG14	
	DIFFERENCE IN ADJUSTED MEAN (95% CI)	**-1.442** (-2.270, 0.613)
	P-VALUE VS PLACEBO	0.00065
	ADCOMS	
	DIFFERENCE IN ADJUSTED MEAN (95% CI)	**-0.050** (-0.074, -0.027)
	P-VALUE VS PLACEBO	0.00002
	ADCS MCI-ADL	
	DIFFERENCE IN ADJUSTED MEAN (95% CI)	**2.016** (1.208, 2.823)
	P-VALUE VS PLACEBO	<0.00001

FIG. 20

	PLACEBO N = 897	LECANEMAB N = 898
ADVERSE EVENT (AE)	82%	89%
SERIOUS ADVERSE EVENT (SAE)	11%	14%
INFUSION-RELATED REACTION SAE	0	1.2%
ARIA-E SAE	0	0.8%
ARIA-H SAE	0.1%	0.6%
AES LEADING TO STUDY DRUG WITHDRAWAL	3%	7%
DEATHS*	7 (0.8%)	6 (0.7%)

FIG. 21

MOST COMMON AES	PLACEBO N = 897	LECANEMAB N = 898
ANY AE	82%	89%
INFUSION-RELATED REACTIONS	7%	26%
AMYLOID-RELATED IMAGING ABNORMALITIES-HEMORRHAGE (ARIA-H)	9%	17%
AMYLOID-RELATED IMAGING ABNORMALITIES-EDEMA (ARIA-E)	2%	13%
HEADACHE	8%	11%
FALL	10%	10%
UNRINARY TRACT INFECTION	9%	9%
COVID-19	7%	7%
BACK PAIN	6%	7%
ARTHRALGIA	7%	6%
DIARRHEA	6%	5%
DIZZINESS	5%	5%
ANXIETY	4%	5%

NO IMPORTANT CHANGES IN LABS, ECG, VITALS

FIG. 22

	PLACEBO N = 897	LECANEMAB N = 898
INFUSION-RELATED REACTION	7%	26%
GRADE 1	5%	9%
GRADE 2	3%	17%
GRADE 3	0	6 (0.7%)
GRADE 4	0	1 (0.1%)

75% OF EVENTS OCCURRED WITH FIRST DOSE
- 6 OF 7 GRADE 3 OR 4 REACTIONS OCCURRED ON THE FIRST DOSE

66% OF PATIENTS WITH INFUSION-RELATED REACTION HAD SINGLE EVENTS

FIG. 23

	PLACEBO N = 897		LECANEMAB N = 898	
ARIA-E	15	1.7%	113	12.6%
ARIA-E BY *APOE4* GENOTYPE				
NONCARRIER	1/286	0.3%	15/278	5.4%
CARRIER	14/611	2.3%	98/620	15.8%
HETEROZYGOUS	9/478	1.9%	52/479	10.9%
HOMOZYGOUS	5/133	3.8%	46/141	32.6%
SYMPTOMATIC ARIA-E	0	0	25	2.8%
NONCARRIER	0	0	4/278	1.4%
CARRIER	0	0	21/620	3.4%
HETEROZYGOUS	0	0	8/479	1.7%
HOMOZYGOUS	0	0	13/141	9.2%

FIG. 24



LECANEMAB HOMOZYGOUS
LECANEMAB HETEROZYGOUS
LECANEMAB NONCARRIER
PLACEBO
PROBABILITY OF ARIA-E
0.35
0.30
0.25
0.20
0.15
0.10
0.05
0.00
0 4 12 20 28 36 44 52 60 68 76
VISIT (WEEKS)
NUMBER AT RISK:
LECANEMAB HOMOZYGOUS (N) 141 101 100 91 89 89 88 86 85 83
LECANEMAB HETEROZYGOUS (N) 479 423 410 395 387 381 374 367 362 343
LECANEMAB NONCARRIER (N) 277 255 247 239 231 221 216 211 205 204
PLACEBO (N) 897 879 863 850 822 800 792 777 762 731

FIG. 25A



LECANEMAB HOMOZYGOUS
LECANEMAB NONCARRIER
LECANEMAB HETEROZYGOUS
PLOT AREA
PROBABILITY OF ARIA-E
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 76 80 84 88 92 96 100 104 108 112 116 120
VISIT (WEEKS)
MRI EVALUATIONS:
LECANEMAB HOMOZYGOUS (N) 141 141 116 101 101 100 100 91 89 89 89 89 88 86 86 86 85 85 85 81 76 74 73 73 73 69 67 66 66
LECANEMAB HETEROZYGOUS (N) 479 479 446 423 415 410 404 395 390 387 386 381 381 374 369 367 365 362 360 358 348 335 332 331 329 327 320 303 298 287 282
LECANEMAB NONCARRIER (N) 278 277 259 255 250 247 245 239 235 231 225 221 220 216 214 211 208 205 205 204 203 195 192 190 188 188 184 173 170 169 168

FIG. 25B

	TOTAL ARIA-H				ISOLATED ARIA-H (NO ARIA-E)			
	PLACEBO N = 897		LECANEMAB N = 898		PLACEBO N = 897		LECANEMAB N = 898	
ARIA-H	81	**9.0%**	155	**17.3%**	70	**7.8%**	80	**8.9%**
APOE4 GENOTYPE								
NONCARRIER	12/286	**4.2%**	33/278	**11.9%**	11/286	**3.8%**	23/278	**8.3%**
CARRIER	69/611	**11.3%**	122/620	**19.7%**	59/611	**9.7%**	57/620	**9.2%**
HETEROZYGOUS	41/478	**8.6%**	67/479	**14.0%**	35/478	**7.3%**	40/479	**8.4%**
HOMOZYGOUS	28/133	**21.1%**	55/141	**39.0%**	24/133	**18.0%**	17/141	**12.1%**
SYMPTOMATIC ARIA-H	2	**0.2%**	13	**1.4%**	2	**0.2%**	4	**0.4%**

FIG. 26

	TOTAL ARIA-H				ISOLATED ARIA-H (NO ARIA-E)			
	PLACEBO N = 897		LECANEMAB N = 898		PLACEBO N = 897		LECANEMAB N = 898	
ARIA-H	81	9.0%	155	17.3%	70	7.8%	80	8.9%
MICROHEMORRHAGE	68	7.6%	126	14.0%	63	7.0%	60	6.7%
SUPERFICIAL SIDEROSIS	21	2.3%	50	5.6%	13	1.4%	23	2.6%
INTRACEREBRAL HEMORRHGE (> 1cm)*	2	0.2%	6	0.7%	1	0.1%	4	0.4%

FIG. 27

	ARIA-E		ARIA-H (MICROHEMORRHAGE OR SUPERFICIAL SIDEROSIS)		INTRACEREBRAL HEMORRHAGE	
	PLACEBO	LECANEMAB	PLACEBO	LECANEMAB	PLACEBO	LECANEMAB
NO ANTIPLATELET OR ANTICOAGULATION AT ANY TIME	9/584 (1.5%)	74/545 (13.6%)	49/584 (8.4%)	93/545 (17.1%)	1/584 (0.2%)*	3/545 (0.6%)
EVENT POST ANY ANTIPLATELET (ASPIRIN OR NON-ASPIRIN)	2/243 (0.8%)	30/271 (11.1%)	22/243 (9.1%)	44/271 (16.2%)	1/243 (0.4%)	1/271 (0.4%)
EVENT POST ANY ANTICOAGULATION (ALONE OR WITH ANTIPLATELET)	2/72 (2.8%)	4/79 (5.1%)	7/72 (9.7%)	11/79 (13.9%)	0/72 (0%)	2/79 (2.5%)*

FIG. 28

	MICROHEMORRAGE AT BASELINE?											
	NONCARRIER				HETEROZYGOTE				HOMOZYGOTE			
	PLACEBO		LEC10-BW		PLACEBO		LEC10-BW		PLACEBO		LEC10-BW	
	NO (N=243)	YES (N=43)	NO (N=243)	YES (N=35)	NO (N=402)	YES (N=76)	NO (N=404)	YES (N=75)	NO (N=93)	YES (N=40)	NO (N=110)	YES (N=31)
ARIA	6 (2.5)	6 (14.0)	29 (11.9)	9 (25.7)	30 (7.5)	14 (18.4)	71 (17.6)	21 (28.0)	13 (14.0)	16 (40.0)	40 (36.4)	23 (74.2)
ARIA-E	1 (0.4)	0	13 (5.4)	2 (5.7)	5 (1.2)	4 (5.3)	42 (10.4)	10 (13.3)	3 (3.2)	2 (5.0)	28 (25.5)	18 (58.1)
ARIA-H	6 (2.5)	6 (14.0)	24 (9.9)	9 (25.7)	29 (7.2)	12 (15.8)	48 (11.9)	19 (25.3)	12 (12.9)	16 (40.0)	33 (30.0)	22 (71.0)
ARIA-H, ISOLATED	5 (2.1)	6 (14.0)	16 (6.6)	7 (20.0)	25 (6.2)	10 (13.2)	29 (7.2)	11 (14.7)	10 (10.8)	14 (35.0)	12 (10.9)	5 (16.1)

FIG. 29

NONCARRIER

PLACEBO	# OF MICROHEMORRHAGES AT BASELINE					
	0 (N=243)	1 (N=28)	2 (N=10)	3 (N=4)	4 (N=1)	6 (N=0)
ARIA	6 (2.5)	3 (10.7)	2 (20.0)	1 (25.0)	0	0
ARIA-E	1 (0.4)	0	0	0	0	0
ARIA-H	6 (2.5)	3 (10.7)	2 (20.0)	1 (25.0)	0	0
ARIA-H, ISOLATED	5 (2.1)	3 (10.7)	2 (20.0)	1 (25.0)	0	0

NONCARRIER

LEC10	# OF MICROHEMORRHAGES AT BASELINE					
	0 (N=243)	1 (N=26)	2 (N=5)	3 (N=2)	4 (N=1)	6 (N=1)
ARIA	29 (11.9)	7 (26.9)	1 (20.0)	0	0	1 (100.0)
ARIA-E	13 (5.4)	2 (7.7)	0	0	0	0
ARIA-H	24 (9.9)	7 (27.0)	1 (20.0)	0	0	1 (100.0)
ARIA-H, ISOLATED	16 (6.6)	5 (19.2)	1 (20.0)	0	0	1 (100.0)

HETEROZYGOTE

PLACEBO	# OF MICROHEMORRHAGES AT BASELINE					
	0 (N=402)	1 (N=49)	2 (N=12)	3 (N=10)	4 (N=5)	6 (N=0)
ARIA	30 (7.5)	8 (16.3)	2 (16.7)	3 (30.0)	1 (20.0)	0
ARIA-E	5 (1.2)	1 (2.0)	1 (8.3)	1 (10.0)	1 (20.0)	0
ARIA-H	29 (7.2)	7 (14.3)	2 (16.7)	2 (20.0)	1 (20.0)	0
ARIA-H, ISOLATED	25 (6.2)	7 (14.3)	1 (8.3)	2 (20.0)	0	0

HETEROZYGOTE

LEC10	# OF MICROHEMORRHAGES AT BASELINE					
	0 (N=404)	1 (N=51)	2 (N=15)	3 (N=6)	4 (N=3)	6 (N=0)
ARIA	71 (17.6)	13 (25.5)	5 (33.3)	1 (16.7)	2 (66.7)	0
ARIA-E	42 (10.4)	7 (13.7)	1 (6.7)	1 (16.7)	1 (33.3)	0
ARIA-H	48 (11.9)	11 (21.6)	5 (33.3)	1 (16.7)	2 (66.7)	0
ARIA-H, ISOLATED	29 (7.2)	6 (11.8)	4 (26.7)	0	1 (33.3)	0

HOMOZYGOTE

PLACEBO	# OF MICROHEMORRHAGES AT BASELINE					
	0 (N=93)	1 (N=22)	2 (N=14)	3 (N=2)	4 (N=2)	6 (N=0)
ARIA	13 (13.98)	5 (22.73)	7 (50.00)	2 (100)	2 (100)	0 (0)
ARIA-E	3 (3.23)	0 (0)	2 (14.29)	0 (0)	0 (0)	0 (0)
ARIA-H	12 (12.90)	5 (22.73)	7 (50.00)	2 (100)	2 (100)	0 (0)
ARIA-H, ISOLATED	10 (10.75)	5 (22.73)	5 (35.71)	2 (100)	2 (100.0)	0 (0)

HOMOZYGOTE

LEC10	# OF MICROHEMORRHAGES AT BASELINE					
	0 (N=110)	1 (N=20)	2 (N=9)	3 (N=1)	4 (N=1)	6 (N=0)
ARIA	40 (36.36)	13 (65.00)	8 (88.89)	1 (100)	1 (100)	0 (0)
ARIA-E	28 (25.45)	11 (55.00)	6 (66.67)	0 (0)	1 (100)	0 (0)
ARIA-H	33 (30.00)	12 (60.00)	8 (88.89)	1 (100)	1 (100)	0 (0)
ARIA-H, ISOLATED	12 (10.91)	2 (10.00)	2 (22.22)	1 (100)	0 (00)	60 (0)

FIG. 30




TREATMENT A: 10mg/kg IV OVER 1 HOUR; TREATMENT B: 700mg SC
LINEAR PLOT
MEAN CONCENTRATION (ug/mL)
400
300
200
100
0
-100
0
200
400
600
800
1000
1200
NOMINAL TIME (h)
A
B
LOG-SCALED PLOT
MEAN CONCENTRATION (ug/mL)
1000
100
10
1
0.1
0.01
0.001
0
200
400
600
800
1000
1200
NOMINAL TIME (h)
A
B

FIG. 31


LINEAR PLOT
MEAN CONCENTRATION (ug/mL)
120
80
40
0
-40
0
200
400
600
800
1000
1200
NOMINAL TIME (h)
NON- JAPANESE
JAPANESE



LOG-SCALED PLOT
MEAN CONCENTRATION (ug/mL)
1000
100
10
1
0.1
0.01
0.001
0
200
400
600
800
1000
1200
NOMINAL TIME (h)
NON- JAPANESE
JAPANESE

FIG. 32




FIG. 33A




FIG. 33B




FIG. 34



50000
40000
30000
20000
10000
0
AUC0-INF (h*µg/ mL)
O
AI
VIAL/SYRINGE
TREATMENT

FIG. 35



AUC0-t (h*µg/ mL)
40000
30000
20000
10000
0
VIAL/SYRINGE
AI
TREATMENT

FIG. 36



PHASE:
PERIOD:
DAY/ MONTH:
PRERANDOMIZATION
SCREENING
BASELINE
≤60 DAYS +15 DAY WINDOW[a] (+5 DAYS FOR Tau PET)
RANDOMIZATION
R
DAY 1
BAN2401 - 10 mg/kg IV BIWEEKLY
PLACEBO - IV BIWEEKLY
6 MONTHS
12 MONTHS
18 MONTHS
EXTENSION
BAN2401 - 10 mg/kg IV BIWEEKLY
BAN2401 - 360 mg SC WEEKLY - AI[f]
BAN2401 - 720 mg SC WEEKLY - VIAL AND SYRINGE[c]
BAN2401 - 720 or 500 mg SC WEEKLY - AI[e]
DE NOVO SUBJECTS DAY 1[d]
3-MONTH FOLLOW-UP[b]
66 MONTHS

FIG. 37



10mg/kg/BW iv VS 720mg/W sc
AUC (ug*h/mL)
80000
70000
60000
50000
40000
30000
10000
10000
0
40
50
60
70
80
90
100
110
120
BW (kg)
sc
AUCsc
iv
AUCiv
10mg/kg/BW IV VS 720mg/W SC
AUCsc/AUCiv
1.9
1.8
1.7
1.6
1.5
1.4
1.3
1.2
1.1
1
0.9
0.8
0.7
0.6
0.5
40
50
60
70
80
90
100
110
120
BW (kg)
sc/iv
sc/iv

FIG. 38



STUDY 301 CORE +OLE mg/kg IV
STUDY 301 OLE AI SUBSTUDY
AUTO- INJECTOR
IV
0
200
400
600
AVERAGE STEADY CONCENTRATION (ug/mL)

FIG. 39



OBSERVED IV LEC10-BW
PROJECTED 500mg QW SC AI
AUTO- INJECTOR
IV
400
300
200
100
AVERAGE STEADY- STATE CONCENTRATION (ug/mL)

FIG. 40



AMYLOID PET (CENTILOID)
150
100
50
0
0
8
16
24
32
40
48
56
64
72
TIME (WEEK)
10 mg/kg IV BW
500 mg SC AI QW

FIG. 41



CHANGE IN CDR-SB
-1
0
1
2
3
4
TIME (WEEK)
0
8
16
24
32
40
48
56
64
72
10 mg/kg IV BW
500 mg SC AI QW

FIG. 42



AMYLOID POSITIVE AT 18 MONTHS
AMYLOID NEGATIVE AT 18 MONTHS
AMYLOID PET (CENTILOID)
100
75
50
25
0
0
6
12
18
24
30
36
42
48
STUDY MONTH
TIME OF MAINTENENCE INITIATION
18 MONTHS
24 MONTHS
CONTINUOUS LEC10-BW
PLACEBO

FIG. 43



AMYLOID POSITIVE AT 18 MONTHS
AMYLOID NEGATIVE AT 18 MONTHS
CDR-SB, CHANGE FROM BASELINE
0
1
2
3
4
5
6
7
8
9
0
6
12
18
24
30
36
42
48
STUDY MONTH
TIME OF MAINTENENCE INITIATION
18 MONTHS
24 MONTHS
CONTINUOUS LEC10-BW
PLACEBO

FIG. 44



BASELINE AMYLOID < 60CL
BASELINE AMYLOID ≥ 60CL
AMYLOID PET (CENTILOID)
100
75
50
25
0
0
6
12
18
24
30
36
42
48
STUDY MONTH
TIME OF MAINTENANCE INITIATION
360 mg AI QW AT 18 MOS.
10 mg/kg IV Q4W AT 18 MOS.
PLACEBO
360 mg AI QW AT 24 MOS.
10 mg/kg IV BW (CONTINUOUS)

FIG. 45



BASELINE AMYLOID < 60CL
BASELINE AMYLOID ≥ 60CL
CDR-SB, MEAN CHANGE FROM BASELINE
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
5.5
6.0
6.5
7.0
7.5
0
6
12
18
24
30
36
42
48
STUDY MONTH
TIME OF MAINTENANCE INITIATION
360 mg AI QW AT 18 MOS.
10 mg/kg IV Q4W AT 18 MOS.
PLACEBO
360 mg AI QW AT 24 MOS.
10 mg/kg IV BW (CONTINUOUS)

FIG. 46



P-tau181
P-TAU181 [95% CI] [pg/mL]
3.75
3.5
3.25
3
2.75
2.5
2.25
2
0
6
12
18
24
30
36
42
48
MONTH
Aβ42/40 RATIO
Aβ42/40 RATIO [95% CI]
0.1
0.098
0.096
0.094
0.092
0.09
0.088
0.086
0.084
0.082
0.08
MONTH
10 mg/kg IV BW (CONTINUOUS)
10 mg/kg IV Q4W AT 18 MONTHS
TIME OF MAINTENANCE INITIATION
360 mg AI Q4W AT 18 MONTHS
360 mg AI Q4W AT 24 MONTHS
PLACEBO

FIG. 47



SOLID LINE= IV,
DOT-DASH LINE= HV PROJECTED FROM STUDY 005,
DASHED LINE= STUDY 301 OLE AI SUBSTUDY
AVERAGE STEADY- STATE CONCENTRATION (ug/mL)
600
400
200
IV
HV
AD
AUTON- INJECTOR

FIG. 48



AVERAGE STEADY- STATE CONCENTRATION (ug/mL)
400
300
200
100
IV
AUTO- INJECTOR

FIG. 49



Time to Worsening of CDR-SB
by 3.0 Points
Event
Rate
0.5
0.4
0.3
0.2
0.1
0
Placebo
Without ARIA
With ARIA
0 3 6 9 12 15 18
Number at risk
Without ARIA (N) 667 650 633 583 557 511 273
With ARIA (N) 192 184 179 168 159 140 71
Placebo (N) 875 847 828 745 712 648 324

FIG. 50